INmune Bio (INMB) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
INmune Bio (INMB) has outperformed Tevogen (TVGN) over the past year, losing 4.5% versus a loss of 81.6%. INmune Bio is the larger company by market cap ($52.5 million vs $44.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INMB | TVGN |
|---|---|---|
| Share price | $1.89 | $6.78 |
| Market cap | $52.45M | $44.15M |
| 1-day change | +3.28% | -3.97% |
| YTD return | +21.15% | -59.03% |
| 1-year return | -4.55% | -81.63% |
| 5-year return | -89.85% | — |
| EPS (TTM) | $-0.67 | $-6.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.60 | $39.00 |
| 52-week low | $1.09 | $3.64 |
| Distance from 52-week high | -27.31% | -82.62% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +270.37% | — |
| Average volume | 378.63K | 9.66K |
| Shares outstanding | 27.75M | 6.51M |
| Employees | 21 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed TVGN by 77.1 percentage points over the past year.
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
INMB vs TVGN FAQ
Which is bigger, INmune Bio or Tevogen?
INmune Bio (INMB) is larger, with a market capitalization of $52.45M compared with $44.15M for Tevogen (TVGN).
Which stock has performed better over the past year, INMB or TVGN?
INMB returned -4.55% over the past 12 months, compared with -81.63% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are INmune Bio and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.